<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2001</study_start_year><condition>Colorectal Adenocarcinoma</condition><condition>Colorectal cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Adenocarcinoma</disease><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2016896</full_dataset_link><location>United States</location><study_start_month>11</study_start_month><keyword>Capecitabine</keyword><keyword>Thalidomide</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma</name><description>The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.</description><dates><creation>2001-11-15</creation></dates><accession>2016896</accession><cross_references><ClinicalTrials___gov>NCT00165217</ClinicalTrials___gov></cross_references></HashMap>